Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways.
about
The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignanciesThe tumor microenvironment shapes hallmarks of mature B-cell malignancies.The Roles of Mesenchymal Stromal/Stem Cells in Tumor Microenvironment Associated with InflammationVisceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.Growth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cellsEgress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.Perturbations of the endocannabinoid system in mantle cell lymphoma: correlations to clinical and pathological features.Cobblestone-area forming cells derived from patients with mantle cell lymphoma are enriched for CD133+ tumor-initiating cellsMesenchymal stromal cells support the viability and differentiation of follicular lymphoma-infiltrating follicular helper T-cells.Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrinsIn vitro study of the effect of small interfering ribonucleic acid on the expression of FOXN1 and B cell-attracting chemokine 1 in thymoma cell linesA critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemiaToll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma.Specificity and biologic activities of novel anti-membrane IgM antibodiesRole of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells.Ibrutinib for mantle cell lymphoma.Novel agents in mantle cell lymphoma.Targeting Wnt pathway in mantle cell lymphoma-initiating cells.Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma.CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma.Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patienRationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.Effects of human umbilical cord-derived mesenchymal stem cells on hematologic malignancies.Physiological Hypoxia (Physioxia) Impairs the Early Adhesion of Single Lymphoma Cell to Marrow Stromal Cell and Extracellular Matrix. Optical Tweezers StudyCyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA
P2860
Q26822700-EC9B5350-81F3-430A-BDA5-245009B370F2Q27687567-D8B7466A-0656-453B-B748-CDE3F22579E9Q28073691-F5D7F388-8C35-46A1-B255-DCE6A3AC6F63Q30201915-81D6224C-97ED-42CA-A2DD-E1E201819D72Q33597756-649316FA-1956-4B33-BA5D-A34604C27A51Q34037828-E624670A-4C10-4BE4-B20B-7F226CD0351FQ34042407-C069070E-D554-447E-811B-751A12B9E264Q34199935-8F3F5ACD-063A-4058-935C-817D3F3DCC2BQ34667539-1B48E356-CD5D-4700-945F-2C3DDA6275B1Q35144981-AE2F6F12-AA3D-4933-AF08-3E82B24C44B8Q35170217-156FF84C-C2EF-4B16-B711-D7BB5C27A90BQ35559414-85739CFE-0CE0-4943-B5A3-1CF1AA598E02Q35663561-25EDB490-9EB4-45C4-BD22-14A290023A64Q35794593-ED1AE59C-E526-4390-BFD7-0D67F77FB7AAQ36001708-EA4B440D-6845-4BC1-B0C4-18624ACFCF27Q36161658-DA3CF8D7-D6BB-4C77-BAD4-CAF4CFB04ED4Q36370860-A435C5DB-8AC9-4B2A-B4C8-6D45EA11187CQ38694168-0BF0BB5E-A1E7-4567-B585-1302FB86C77AQ39290199-75783FCC-A4E1-4615-83EF-4D032E2E06AAQ42558443-B223F9E5-7123-4E96-A206-FF0DA2753F10Q47232472-C0B18E3A-4D81-40BC-9B8E-B58C7BE94E18Q47549122-33C8171D-2F8E-4A7F-BDC5-34EAEA8AF565Q47699487-78FF665E-545B-465A-99B8-9BEA354C17DEQ49959959-AC83DFB5-74BF-4AB8-BA85-AC69C6FDCC01Q53730905-13DBC25B-1FF7-43BA-985B-2A5941B4D313Q55202662-2A4BE6A1-0972-4913-BF6B-703544675614Q56887737-12E31CBC-581F-407B-BC52-C6C246F45554Q58765200-D1A18D47-C0E9-4912-A802-7FA70080BEEB
P2860
Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Mesenchymal stromal cells prot ...... al nuclear factor κB pathways.
@en
Mesenchymal stromal cells prot ...... al nuclear factor κB pathways.
@nl
type
label
Mesenchymal stromal cells prot ...... al nuclear factor κB pathways.
@en
Mesenchymal stromal cells prot ...... al nuclear factor κB pathways.
@nl
prefLabel
Mesenchymal stromal cells prot ...... al nuclear factor κB pathways.
@en
Mesenchymal stromal cells prot ...... al nuclear factor κB pathways.
@nl
P2093
P2860
P1433
P1476
Mesenchymal stromal cells prot ...... al nuclear factor κB pathways.
@en
P2093
Arnold B Rabson
Céline Gélinas
Daniel J Medina
Lauri Goodell
Roger K Strair
P2860
P304
P356
10.3324/HAEMATOL.2011.040659
P577
2012-02-27T00:00:00Z